Study #2019-0216
GBM AGILE Global Adaptive Trial Master Protocol: An International, Seamless Phase II/III Response Adaptive Randomization Platform Trial Designed To Evaluate Multiple Regimens In Newly Diagnosed and Recurrent Glioblastoma (GBM)
MD Anderson Study Status
Enrolling
Treatment Agent
Temozolomide, Lomustine, Regorafenib, Paxalisib, VAL-083, VT1021, Troriluzole, ADI-PEG 20
Description
Glioblastoma (GBM) adaptive, global, innovative learning environment (GBM AGILE) is an international, seamless Phase II/III response adaptive randomization platform trial designed to evaluate multiple therapies in newly diagnosed (ND) and recurrent GBM.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Glioblastoma
Study phase:
Phase II/III
Physician name:
Shiao-Pei Weathers
Department:
Neuro-Oncology
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.